Free shipping on all orders over $ 500

OXA (17-33)

Cat. No. M9943

All AbMole products are for research use only, cannot be used for human consumption.

OXA (17-33) Structure
Size Price Availability Quantity
1mg USD 340  USD340 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

OXA (17-33) is a potent and selective peptide orexin OX1 receptor agonist (EC50 values are 8.29 and 187 nM for OX1 and OX2 receptors respectively).

Sequence: Tyr-Glu-Leu-Leu-His-Gly-Ala-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Leu-NH2

Chemical Information
Molecular Weight 1749
Formula C79H125N23O22
CAS Number 343268-91-7
Solubility (25°C) Water 1 mg/mL
Storage -20°C, dry, sealed
References

[1] Nadezhda A German, et al. ACS Med Chem Lett. Truncated Orexin Peptides: Structure-Activity Relationship Studies

Related OX Receptor Products
CVN766 

CVN766 is an orally active inhibitor of orexin 1 receptor antagonist with blood-brain permeability with the IC50 values of 8 nM and >10 μM for OX1R and OX2R, respectively.

Nivasorexant

Nivasorexant is a potent orexin receptor antagonist.

[Ala11, D-Leu15]-Orexin B(human)

[Ala11,D-Leu15]-Orexin B(human) is a potent and selective orexin-2 receptor (OX2) agonist.

Orexin B, rat, mouse

Orexin B, rat, mouse (Rat orexin B) is an endogenous agonist at Orexin receptor with Kis of 420 and 36 nM for OX1 and OX2, respectively.

Hypocretin (70-98), human

Hypocretin (70-98), human is a polypeptide that is capable of binding to an orexin receptor OX1R and promotes apoptosis.

  Catalog
Abmole Inhibitor Catalog




Keywords: OXA (17-33) supplier, OX Receptor, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.